GRAIL, Inc. (GRAL) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Negative margins ⢠Financing-dependent GRAL is liquid and conservatively capitalized with low leverage and strong cash/equity cushions, but suffers from severe negative gross margins, massive operating losses and negative free cash flow, forcing reliance on external financing.
Price Behavior
Key Price Behavior Insights: ⢠Shortâterm downtrend ⢠Defined $43 low ⢠Midâ$50s reversal Support Level: $43.00 Resistance Level: $54.00â$58.10; larger barrier ~$100 GRAL is in a shortâterm downtrend below its lastâmonth SMA after plunging from the ~95â105 area to the lowâ$40s, with immediate support at $43 â failure to hold $43 keeps downside risk high while a rally above the midâ$50s would signal a shortâterm reversal.
Sentiment & News
Key News Insights: ⢠Trial failure ⢠Sharp stock drop ⢠Legal probes Grail's NHSâGalleri trial miss spurred a ~50% stock collapse, surge in options activity and securities investigations despite rising Galleri revenue, a PMA submission and cash runway into 2030.
AI Summary
GRAL has shifted from an approvalâoption growth bet to a cashârich, executionâdependent commercial company where nearâterm value now hinges on demonstrable perâtest grossâmargin improvement and positive PMA/NHS readouts to avoid dilution or impairment, so investors should only add exposure if they can monitor clinical/regulatory milestones and require clear, repeatable unit economics before increasing position.
Description
GRAIL, Inc. is a biotechnology firm based in Menlo Park, California, established in 2015. The company develops blood-based tests intended to detect cancer at early stages in asymptomatic individuals and to support faster diagnostic resolution when cancer is suspected, as well as tests for minimal residual disease and other post-diagnostic uses. GRAIL previously operated as a subsidiary of Illumina, Inc.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 26 | Dec 3 | GRAL | GRAIL, Inc. | Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside. | Closed | -8.1% |